# A Study Investigating the Safety, Absorption and Elimination of GLPG3312, a New Drug in the Treatment of Inflammatory Diseases

> **NCT03800472** · PHASE1 · COMPLETED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 95 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** GLPG3312 IR
- **DRUG:** Placebo
- **DRUG:** GLPG3312 MR
- **DRUG:** GLPG3312 FE MR
- **DRUG:** GLPG3312 MR
- **DRUG:** GLPG3312 MR
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03800472
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-15
- **Primary completion:** 2020-03-10
- **Final completion:** 2020-03-10
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2020-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03800472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03800472, "A Study Investigating the Safety, Absorption and Elimination of GLPG3312, a New Drug in the Treatment of Inflammatory Diseases". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03800472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*